FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation

Inhibition of Urease by Disulfiram, an FDA-Approved Thiol Reagent Used in Humans.

Urease is a nickel-dependent amidohydrolase that catalyses the decomposition of urea into carbamate and ammonia, a reaction that constitutes an important source of nitrogen for bacteria, fungi and plants. It is recognized as a potential antimicrobial target with an impact on medicine, agriculture, and the environment. The list of possible urease inhibitors is continuously increasing, with a spe...

The gasdermin-D pore: Executor of pyroptotic cell death

Pyroptosis is a lytic type of programmed cell death that is initiated in response to pathogenor host-derived perturbations of the cytosol. It is characterized by cell swelling, lysis, and the release of cytoplasmic content; thus restricting the replication of intracellular pathogens and attracting effector cells of the immune system. The name pyroptosis derives from the Greek pyro (fire or feve...

Gasdermin D Exerts Anti-inflammatory Effects by Promoting Neutrophil Death

Gasdermin D (GSDMD) is considered a proinflammatory factor that mediates pyroptosis in macrophages to protect hosts from intracellular bacteria. Here, we reveal that GSDMD deficiency paradoxically augmented host responses to extracellular Escherichia coli, mainly by delaying neutrophil death, which established GSDMD as a negative regulator of innate immunity. In contrast to its activation in ma...

Zarxio (Filgrastim-sndz): The First Biosimilar Approved by the FDA.

Zarxio (filgrastim-sndz), a biosimilar for the treatment of severe chronic neutropenia.

FDA-Approved Drugs to Treat Schizophrenia.